Impact of TET2 mutation on prognosis in either de novo or secondary AML remains controversial. 6, 8, 9 In addition, the frequency and impact of TET2 mutations on initial features and response to treatment in secondary AML (sAML) have not yet been fully examined.
In this retrospective study, we analyzed the TET2 gene coding sequence in a cohort of 247 sAML recorded as myelodysplasia-related changes (MRC) AML and therapy-related (TR) AML based on the WHO 2008 classification. 10 Patients with TET2 mutations (19.8%) presented with particular characteristics and had the same prognosis than patients with wild-type
TET2.
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The Table 1 ). The overall frequency of TET2 mutations was comparable to that reported in smaller cohorts of AML or de novo AML. 8, 9 However, a recent study including 783 patients with AML aged 16 to 60 years showed a lower frequency (7.6%) than that observed in our cohort which median age was 66 [57 -74].
14 Clinical and biological characteristics of patients harbouring TET2 mutation were described in Table 2 ).
In the whole cohort (n=247), 69 (28%) patients had a normal karyotype (NK 8 CKIT-D816V mutations are rare in AML, however they appeared to be more frequent in TET2 mutated patients as reported in systemic mastocytosis. 17 In NK patients, TET2 remained not associated with NPM1 or FLT3-ITD or FLT3-D835 mutations (Table 2B ). In TR-AML, TET2 mutations are rare (8%) compared to TP53 mutations detected in more than 20% of patients, as previously reported. 18 Information on treatments was available in 225 (91%) of patients. Treatment was best supportive care in 51, hypomethylating agents in 9, IC in 158 followed by alloSCT in 22, others in 7. The repartition of treatments was not different between mutated and wild-type patients, except for alloSCT which was less frequent in the TET2 mutated group, probably because of older age (P<0.05 ; Figure 1A ). In addition, TET2 mutations had no impact on OS in the group of MRC-AML ( Figure 1B ) while the impact was not analysable in the TR-AML.
Finally, we looked at OS in AML treated by IC depending on the presence of either a normal or a monosomal karyotype (MK) according to Breems and colleagues. 19 NK improves OS ( Figure 1C ) and TET2 had no impact on OS in NK AML ( Figure 1D ). MK was a very poor prognosis factor ( Figure 1E ). Although the median OS was 3 months in wild-type TET2 patients (n=46) and 11.4 months in mutated TET2 patients (n=4) with MK, the trend to better survival of TET2 mutated patients was not significant (P=0.305), possibly because of small size of the MK subgroup ( Figure 1F ). These results are consistent with two reports
showing that OS was independent of TET2 status 6, 9 and different from the findings of AbdelWahab and colleagues demonstrating an unfavourable impact. 8 In conclusion, the frequency TET2 mutations appear to be higher in sAML than in de novo AML and associated with MRC-AML rather than TR-AML. They did not associate with other mutations reported as prognosis factors in AML or modify the poor prognosis of sAML.
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